News
A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...
3d
Clinical Trials Arena on MSNArrowhead commences dosing in Phase I/IIa obesity treatment trialThe trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.
When combined with a GLP-1 receptor agonist, the Activin E antibody produced additive effects, reducing total fat mass by 77%. Subcutaneous fat loss increased to 74%, while visceral fat depots ...
Arrowhead Pharmaceuticals has submitted an application to the New Zealand Medicines and Medical Devices Safety Authority seeking clearance to commence a Phase I/IIa trial of its investigational ...
Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. To date, it is the only approved medicine for both newly diagnosed and previously treated myelofibrosis ...
By reducing the activity of Activin E and its receptors, researchers believe it may be possible to develop therapeutics that could decrease internal abdominal fat, while preserving muscle mass to ...
Momelotinib is designed to inhibit 3 signaling pathways including Janus kinase (JAK) 1, JAK2, and activin A receptor type 1 (ACVR1). The Company believes that the inhibition of JAK1 and JAK2 may ...
Next, Dr Vannucchi describes the final analysis from a phase 3 study evaluating jaktinib, a novel JAK and activin A receptor type 1 (ACVR1) inhibitor, compared with hydroxyurea in patients with MF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results